Liposomes

The advent of closed bilayer phospholipid systems, known as liposomes, was documented in 1965 and swiftly proposed as a means of delivering drugs. The groundbreaking efforts of numerous liposome researchers spanning nearly five decades have yielded significant technical advancements. These include remote drug loading, homogenization through extrusion, long-circulating (PEGylated) liposomes, liposomes with triggered release mechanisms, liposomes incorporating nucleic acids and polymers, ligand-targeted liposomes, and liposomes combining multiple drugs. Such progress has paved the way for numerous clinical trials across diverse domains, encompassing the delivery of anti-cancer, anti-fungal, and anti-biotic drugs, gene medicines, as well as anesthetics and anti-inflammatory drugs. Several liposomal products are already available on the market, with many more in the development pipeline. Liposomes represent one of the pioneering nanomedicine delivery systems to successfully transition from theoretical concept to clinical application, now firmly established as a technology platform with substantial clinical acceptance [2013 Allen].